These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

264 related articles for article (PubMed ID: 28202490)

  • 1. Merck ends trial of potential Alzheimer's drug verubecestat.
    Hawkes N
    BMJ; 2017 Feb; 356():j845. PubMed ID: 28202490
    [No Abstract]   [Full Text] [Related]  

  • 2. Chronic Verubecestat Treatment Suppresses Amyloid Accumulation in Advanced Aged Tg2576-AβPPswe Mice Without Inducing Microhemorrhage.
    Villarreal S; Zhao F; Hyde LA; Holder D; Forest T; Sondey M; Chen X; Sur C; Parker EM; Kennedy ME
    J Alzheimers Dis; 2017; 59(4):1393-1413. PubMed ID: 28800329
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lessons that can be learnt from the failure of verubecestat in Alzheimer's disease.
    Doggrell SA
    Expert Opin Pharmacother; 2019 Dec; 20(17):2095-2099. PubMed ID: 31423903
    [No Abstract]   [Full Text] [Related]  

  • 4. Randomized Trial of Verubecestat for Mild-to-Moderate Alzheimer's Disease.
    Egan MF; Kost J; Tariot PN; Aisen PS; Cummings JL; Vellas B; Sur C; Mukai Y; Voss T; Furtek C; Mahoney E; Harper Mozley L; Vandenberghe R; Mo Y; Michelson D
    N Engl J Med; 2018 May; 378(18):1691-1703. PubMed ID: 29719179
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Randomized Trial of Verubecestat for Prodromal Alzheimer's Disease.
    Egan MF; Kost J; Voss T; Mukai Y; Aisen PS; Cummings JL; Tariot PN; Vellas B; van Dyck CH; Boada M; Zhang Y; Li W; Furtek C; Mahoney E; Harper Mozley L; Mo Y; Sur C; Michelson D
    N Engl J Med; 2019 Apr; 380(15):1408-1420. PubMed ID: 30970186
    [TBL] [Abstract][Full Text] [Related]  

  • 6. BACE inhibition causes rapid, regional, and non-progressive volume reduction in Alzheimer's disease brain.
    Sur C; Kost J; Scott D; Adamczuk K; Fox NC; Cummings JL; Tariot PN; Aisen PS; Vellas B; Voss T; Mahoney E; Mukai Y; Kennedy ME; Lines C; Michelson D; Egan MF
    Brain; 2020 Dec; 143(12):3816-3826. PubMed ID: 33253354
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Further analyses of the safety of verubecestat in the phase 3 EPOCH trial of mild-to-moderate Alzheimer's disease.
    Egan MF; Mukai Y; Voss T; Kost J; Stone J; Furtek C; Mahoney E; Cummings JL; Tariot PN; Aisen PS; Vellas B; Lines C; Michelson D
    Alzheimers Res Ther; 2019 Aug; 11(1):68. PubMed ID: 31387606
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bad news and good news in AD, and how to reconcile them.
    Knopman DS
    Nat Rev Neurol; 2019 Feb; 15(2):61-62. PubMed ID: 30622292
    [No Abstract]   [Full Text] [Related]  

  • 9. What Have We Learned from Expedition III and EPOCH Trials? Perspective of the CTAD Task Force.
    Aisen PS; Siemers E; Michelson D; Salloway S; Sampaio C; Carrillo MC; Sperling R; Doody R; Scheltens P; Bateman R; Weiner M; Vellas B
    J Prev Alzheimers Dis; 2018; 5(3):171-174. PubMed ID: 29972209
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Emerging drugs to reduce abnormal β-amyloid protein in Alzheimer's disease patients.
    Panza F; Seripa D; Solfrizzi V; Imbimbo BP; Lozupone M; Leo A; Sardone R; Gagliardi G; Lofano L; Creanza BC; Bisceglia P; Daniele A; Bellomo A; Greco A; Logroscino G
    Expert Opin Emerg Drugs; 2016 Dec; 21(4):377-391. PubMed ID: 27678025
    [TBL] [Abstract][Full Text] [Related]  

  • 11. β-secretase inhibitors for Alzheimer's disease: heading in the wrong direction?
    Selkoe D
    Lancet Neurol; 2019 Jul; 18(7):624-626. PubMed ID: 31202466
    [No Abstract]   [Full Text] [Related]  

  • 12. Retinal Optical Coherence Tomography Metrics Are Unchanged in Verubecestat Alzheimer's Disease Clinical Trial but Correlate with Baseline Regional Brain Atrophy.
    Sergott RC; Raji A; Kost J; Sur C; Jackson S; Locco A; Patel A; Furtek C; Mattson B; Egan MF
    J Alzheimers Dis; 2021; 79(1):275-287. PubMed ID: 33252075
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neuropathology of a patient with Alzheimer disease treated with low doses of verubecestat.
    Querol-Vilaseca M; Sirisi S; Molina-Porcel L; Molina B; Pegueroles J; Ferrer-Raventós P; Nuñez-Llaves R; Dols-Icardo O; Balasa M; Iulita MF; Blesa R; Belbin O; Clarimon J; Fortea J; Gelpi E; Sánchez-Valle R; Lleó A
    Neuropathol Appl Neurobiol; 2022 Apr; 48(3):e12781. PubMed ID: 34825396
    [TBL] [Abstract][Full Text] [Related]  

  • 14. BACE inhibitor bust in Alzheimer trial.
    Mullard A
    Nat Rev Drug Discov; 2017 Mar; 16(3):155. PubMed ID: 28248932
    [No Abstract]   [Full Text] [Related]  

  • 15. Discovery of the 3-Imino-1,2,4-thiadiazinane 1,1-Dioxide Derivative Verubecestat (MK-8931)-A β-Site Amyloid Precursor Protein Cleaving Enzyme 1 Inhibitor for the Treatment of Alzheimer's Disease.
    Scott JD; Li SW; Brunskill AP; Chen X; Cox K; Cumming JN; Forman M; Gilbert EJ; Hodgson RA; Hyde LA; Jiang Q; Iserloh U; Kazakevich I; Kuvelkar R; Mei H; Meredith J; Misiaszek J; Orth P; Rossiter LM; Slater M; Stone J; Strickland CO; Voigt JH; Wang G; Wang H; Wu Y; Greenlee WJ; Parker EM; Kennedy ME; Stamford AW
    J Med Chem; 2016 Dec; 59(23):10435-10450. PubMed ID: 27933948
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anti-Aβ agents for mild to moderate Alzheimer's disease: systematic review and meta-analysis.
    Lu L; Zheng X; Wang S; Tang C; Zhang Y; Yao G; Zeng J; Ge S; Wen H; Xu M; Guyatt G; Xu N
    J Neurol Neurosurg Psychiatry; 2020 Dec; 91(12):1316-1324. PubMed ID: 33046560
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cognitive outcomes in trials of two BACE inhibitors in Alzheimer's disease.
    Wessels AM; Lines C; Stern RA; Kost J; Voss T; Mozley LH; Furtek C; Mukai Y; Aisen PS; Cummings JL; Tariot PN; Vellas B; Dupre N; Randolph C; Michelson D; Andersen SW; Shering C; Sims JR; Egan MF
    Alzheimers Dement; 2020 Nov; 16(11):1483-1492. PubMed ID: 33049114
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The BACE1 inhibitor verubecestat (MK-8931) reduces CNS β-amyloid in animal models and in Alzheimer's disease patients.
    Kennedy ME; Stamford AW; Chen X; Cox K; Cumming JN; Dockendorf MF; Egan M; Ereshefsky L; Hodgson RA; Hyde LA; Jhee S; Kleijn HJ; Kuvelkar R; Li W; Mattson BA; Mei H; Palcza J; Scott JD; Tanen M; Troyer MD; Tseng JL; Stone JA; Parker EM; Forman MS
    Sci Transl Med; 2016 Nov; 8(363):363ra150. PubMed ID: 27807285
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Failed Alzheimer's trial does not kill leading theory of disease.
    Abbott A; Dolgin E
    Nature; 2016 Nov; 540(7631):15-16. PubMed ID: 27905452
    [No Abstract]   [Full Text] [Related]  

  • 20. Synthesis of Verubecestat, a BACE1 Inhibitor for the Treatment of Alzheimer's Disease.
    Thaisrivongs DA; Miller SP; Molinaro C; Chen Q; Song ZJ; Tan L; Chen L; Chen W; Lekhal A; Pulicare SK; Xu Y
    Org Lett; 2016 Nov; 18(22):5780-5783. PubMed ID: 27934506
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.